ResearcherUniversity of CataniaNo recent work listed
Saverio Candido
Matched on ORCID iD 0000-0003-1255-6666; OpenAlex author ID A5076971405. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 7
2015: 1 paper · 2016: none · 2017: none · 2018: 2 papers · 2019: 3 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper
Papers 9
- Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines in the presence and absence of WT-TP53. Co-author DOI 10.1016/j.jbior.2021.100840↗
- Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can be regulated by WT-TP53. Co-author DOI 10.1016/j.jbior.2020.100780↗
- Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic c… First author DOI 10.1016/j.jbior.2019.100672↗
- Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. Co-author DOI 10.1016/j.jbior.2018.10.003↗
- Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutrac… Co-author DOI 10.1016/j.jbior.2019.03.002↗
- Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. First author DOI 10.1016/j.jbior.2019.04.003↗
- Metformin influences drug sensitivity in pancreatic cancer cells. Co-author DOI 10.1016/j.jbior.2018.02.002↗
- Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals. Co-author DOI 10.1016/j.jbior.2018.06.002↗
- Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells. Co-author DOI 10.1016/j.jbior.2015.06.003↗
Closest collaborators
The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Stephen Lee Abrams · 9 shared papers, 2015–2022 · strength 0.73
- Paper Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines … DOI 10.1016/j.jbior.2021.100840↗
- Paper Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can… DOI 10.1016/j.jbior.2020.100780↗
- Paper Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and… DOI 10.1016/j.jbior.2019.100672↗
- Melchiorre Cervello · 9 shared papers, 2015–2022 · strength 0.73
- Paper Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines … DOI 10.1016/j.jbior.2021.100840↗
- Paper Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can… DOI 10.1016/j.jbior.2020.100780↗
- Paper Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and… DOI 10.1016/j.jbior.2019.100672↗
- James Andrew McCubrey · 9 shared papers, 2015–2022 · strength 0.73
- Paper Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines … DOI 10.1016/j.jbior.2021.100840↗
- Paper Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can… DOI 10.1016/j.jbior.2020.100780↗
- Paper Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and… DOI 10.1016/j.jbior.2019.100672↗
- Agnieszka Gizak · 6 shared papers, 2018–2021 · strength 0.48
- Paper Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can… DOI 10.1016/j.jbior.2020.100780↗
- Paper Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and… DOI 10.1016/j.jbior.2019.100672↗
- Paper Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. DOI 10.1016/j.jbior.2018.10.003↗
- Shaw M. Akula · 5 shared papers, 2019–2022 · strength 0.48
- Paper Effects of the MDM2 inhibitor Nutlin-3a on sensitivity of pancreatic cancer cells to berberine and modified berberines … DOI 10.1016/j.jbior.2021.100840↗
- Paper Sensitivity of pancreatic cancer cells to chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals can… DOI 10.1016/j.jbior.2020.100780↗
- Paper Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and… DOI 10.1016/j.jbior.2019.100672↗
- Marco Falasca · 2 shared papers, 2018–2020 · strength 0.15
- Paper Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and… DOI 10.1016/j.jbior.2019.100672↗
- Paper Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutic… DOI 10.1016/j.jbior.2018.06.002↗
- Timothy Louis Fitzgerald · 1 shared paper, 2015 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.